Chimeric antigen receptor (CAR)–modified T cells that target the CD19 antigen present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL). Although cytokine release syndrome (CRS) and neurotoxicity have emerged as predominant noninfectious complications of CD19 CAR T-cell therapy, infections associated with this treatment modality have not been well documented.

中文翻译：

---

细胞因子释放综合征等级作为嵌合抗原受体T细胞治疗复发或难治性B细胞急性淋巴细胞白血病患者感染的预测指标

靶向CD19抗原的嵌合抗原受体（CAR）修饰的T细胞为治疗复发性B细胞急性淋巴细胞白血病（B-ALL）提供了一种新的有希望的疗法。尽管细胞因子释放综合征（CRS）和神经毒性已成为CD19 CAR T细胞治疗的主要非感染性并发症，但与这种治疗方式相关的感染尚未得到充分记录。